Endava plc (DAVA) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman

Endava shares fell more than 25% on September 22, 2026, after the company disclosed an internal accounting investigation, placed CFO Mark Thurston on administrative leave, and said it would delay its Q4 and FY 2026 reports. Hagens Berman is investigating potential securities-law violations and possible historical restatements; these are allegations, not established findings. The proposed class period is September 4, 2025–September 21, 2026, with a lead-plaintiff deadline of November 30, 2026.

Analysis

The lawsuit is a weak standalone signal: a plaintiffs’ firm’s investigation and solicitation do not establish liability, and litigation is likely a long-duration overhang rather than the next earnings driver. The more consequential issue is whether the accounting review delays reliable financials or changes reported revenue, cash flow, or the credibility of management’s AI-growth narrative. If customer or supplier agreement accounting affects revenue timing, the downside could extend beyond a one-time restatement: investors may discount future bookings and AI-related growth claims until controls and reporting are demonstrably dependable. That could also raise diligence costs for customers and make competitors more credible alternatives, though there is no evidence here of customer losses or a specific beneficiary.

Near term, the interim CFO, audit findings, and delayed filings dominate; over 1–3 months, scope and timing of any restatement and the auditor’s conclusions are the key catalysts. Over 6–18 months, governance remediation and evidence of underlying demand matter more than the class action. The contrarian point is that the legal headline may add little after the prior sharp repricing; the risk is treating that decline as a floor before financial statements are trustworthy. The thesis weakens materially if filings arrive promptly with no material adjustments, controls are validated, and operating metrics support the AI positioning. No valuation, borrow, options-implied volatility, or restatement data are supplied, so avoid a price target or options trade.

Key Decisions for Investors

• Do not buy DAVA solely on the assumption that the initial selloff fully captures the risk. Keep exposure light until the company files delayed reports and discloses the review’s scope, any adjustments, and the auditor’s position.
• For existing exposure, use any relief rally before credible filings to reassess or reduce risk rather than adding mechanically. A tactical short is only attractive if shares rebound while reporting uncertainty remains; cap risk because a clean resolution could trigger a sharp recovery.
• Set alerts for filing dates, restatement size and periods affected, auditor or control conclusions, and revisions to revenue, cash-flow, or bookings guidance. A material restatement or further delay would reinforce the downside case; clean filings and validated controls would falsify it.
• Treat the class action itself as a secondary, multi-year uncertainty—not a near-term earnings estimate. Revisit the AI thesis only against disclosed operating evidence, not the complaint’s allegations.